Plus Therapeutics Announces Presentation of Data from the ReSPECT-GBM Trial and Plans for Treating Pediatric Brain Cancer (GlobeNewswire) - Aug 21, 2021 - "In addition, the Company presented plans for a proposed two-part, Phase 1 dose-finding study to be followed by an expansion cohort to explore the efficacy of 186RNL in pediatric patients with brain tumors. Part one of the trial will enroll up to 18 subjects to determine the maximum feasible dose of 186RNL administered by CED with the tumor diameter limited to four centimeters and a volume of 34 milliliters. While Part two of the study will independently evaluate 186RNL in up to 39 patients across three different cohorts based on their specific disease diagnosis...Patient enrollment for this study is expected to begin by mid 2022."
Clinical protocol • Enrollment status • Brain Cancer • Oncology
|